Stay updated on Nivolumab for IDH Mutant Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.

Latest updates to the Nivolumab for IDH Mutant Gliomas Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe ClinicalTrials.gov record for a nivolumab study in recurrent or progressive IDH-mutant gliomas is available, with detailed study information and posted results.SummaryDifference51%

- Check16 days agoChange DetectedThe site revision identifier changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.SummaryDifference1%

- Check30 days agoChange DetectedThe displayed ClinicalTrials.gov revision changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision identifier updates from v3.7.0 to v3.7.1, while the page continues to display a 403 error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the previous detailed study content with an access-restricted view. This reflects an access issue rather than a modification to the study data.SummaryDifference18%

Stay in the know with updates to Nivolumab for IDH Mutant Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.